spacer
home > epc > winter 2003 > extending a patent portfolio
PUBLICATIONS
European Pharmaceutical Contractor

Extending a Patent Portfolio

The pharmaceutical sector is struggling to maintain stock price stability in light of a gap in the drug development pipelines. This article examines some of the strategies available to pharmaceutical companies in order to extend the life of a patent.

The pharmaceutical industry has a very mature appreciation of the strong link between patent protection and the bottom line. No serious player can afford to risk undermining its heavy investment in research and development by allowing major inventions and developments to be copied by competitors. The share prices for pharmaceutical companies have a very close correlation to the life cycle of their drugs, be it in the research and development phase, the launch of products to market or when the patent on a drug approaches the end of its protection, at which point competitors can market their own versions of the drug. As the patent nears the end of its life, analysts will adjust the value of the stock accordingly. Of course, the first thing analysts are interested in is whether the pharmaceutical company can demonstrate stability in sales through a healthy development pipeline.

However, with many patents on major drugs set to expire over the next decade, some of the larger players in the sector are facing increasing scrutiny and pressure to demonstrate shareholder value. One famous case of the massive impact that patent protection can have on a share price is that of Eli Lilly and Prozac®. As the developer of a high profile drug with a large sales volume, Eli Lilly was much lauded in the financial markets. Sales of Prozac reached $2.6 billion per year, and the stock was riding high. This success abruptly ended in August 2000 when, with three years to run on the Prozac patents, a US court effectively held the patents invalid, allowing competitors to bring generic versions to market a lot earlier than expected.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Graham Ruffles, Chartered Patent Attorney and European Patent Attorney at Marks & Clerk

Graham Ruffles is a Chartered Patent Attorney and European Patent Attorney and has been a partner at Marks & Clerk for over 20 years. He graduated in Natural Sciences and subsequently obtained degrees in Organic Chemistry and Biology. He is a European Chemist, a Fellow of the Royal Society of Chemistry and a Chartered Chemist, as well as being a European Biologist, a Member of the Institute of Biology and a Chartered Biologist. During his time at Marks & Clerk, he has gained significant experience of chemical, pharmaceutical and biotechnology patents and related subjects, including medical equipment, polymers and food technology.

spacer
Graham Ruffles
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Organization Updates

Philadelphia, PA – May 20, 2019 – PCI Pharma Services, a leading biopharmaceutical outsourcing services provider, is pleased to announce the following management updates to help drive the company’s future vision, strategy and growth.
More info >>

White Papers

Personalised Medicine - Pharma and Dx Firms Share Wider Horizons

DiagnostikNet-BB

Personalised medicine might be a popular catch-phrase at the moment, but the term often causes confusion, as there is still no uniform definition for it. The expression can include areas as diverse as the measurement of individual risk, early detection using biomarker testing, stratification of patients suffering from a disease and predictions about its course.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement